Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Sarepta Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and competitive edge. Over the past decade, Bristol-Myers Squibb Company and Sarepta Therapeutics, Inc. have showcased contrasting trends in their SG&A expenditures.

Bristol-Myers Squibb Company

From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses have seen a significant increase, peaking in 2022 with a 37% rise from 2014. This growth reflects the company's strategic investments in marketing and administrative capabilities to support its expanding portfolio.

Sarepta Therapeutics, Inc.

Conversely, Sarepta Therapeutics, a smaller player, has experienced a staggering 878% increase in SG&A expenses over the same period. This surge underscores Sarepta's aggressive expansion and investment in its administrative infrastructure to support its innovative therapies.

These trends highlight the diverse strategies employed by pharmaceutical giants and emerging biotech firms in navigating the competitive landscape.